Home / Health / Moderna Vaccine Shows 5-Year Promise Against Melanoma
Moderna Vaccine Shows 5-Year Promise Against Melanoma
1 Jun
Summary
- Personalized mRNA vaccine nearly halved melanoma return risk over five years.
- Nearly 70% of patients remained cancer-free with the vaccine after five years.
- Side effects were similar to COVID-19 vaccines, lasting only a few days.
An experimental personalized mRNA vaccine from Moderna has shown remarkable success in clinical trials, significantly reducing the recurrence of melanoma, the deadliest form of skin cancer. Presented at the American Society of Clinical Oncology's annual meeting, the research indicates that this vaccine, when added to standard immunotherapy, nearly halved the risk of melanoma returning after five years.
In the trial involving patients with Stage 3 melanoma, approximately 70% of those who received the vaccine remained cancer-free five years post-treatment. This contrasts with the 49% cancer-free rate observed in the group receiving only standard immunotherapy. The vaccine's development leverages advances in mRNA technology, training the immune system to identify and eliminate lingering cancer cells or new ones that emerge.
Experts suggest that if larger trials confirm these findings, this approach could be "paradigm-shifting" for cancer treatment, not just for melanoma but potentially for other cancers as well. The observed side effects were generally mild, resembling those of mRNA COVID-19 vaccines, such as flu-like symptoms that resolved within a few days. Researchers are awaiting results from a larger Phase 3 trial to further validate the vaccine's efficacy and safety.
